Via Google Translate:The FCM-UNA, through the Hospital de Clínicas, conducted the first Phase 3 clinical study to evaluate the safety, tolerability and immunogenicity of the MVC COV 1901 vaccine against SARS CoV 2 from the Taiwanese Pharmaceutical Medigen Vaccine Biologics Corp.